The market for biopharmaceutical initial public offerings in the US has grown more impressive in each quarter of 2020 in almost every way. There were nine IPOs in the first quarter, 20 in the second and 29 in the third quarter for a total of 58 first-time offerings by drug developers – eight more than the 50 IPOs for all of 2019.
[Sidebar#SC142501]






